2025-07-31 2025-07-31 , online online, 1,290 € zzgl. MwSt. Claire Blaney https://www.forum-institut.de/seminar/25112003-hta-for-pharmaceuticals-in-europe-assessment-logics-practical-trends/referenten/25/25_11/25112003-hta-for-pharmaceuticals-in-europe-assessment-logics-practical-trends_blaney-claire.jpg HTA for Pharmaceuticals in Europe: Assessment Logics & Practical Trends

Online seminar on HTA logics, national differences (Germany, France, UK, Nordic countries) and EU HTA regulation - essential insights for pharmaceutical market access professionals.

Topics
  • Principles of HTA in Europe and national implications
  • Assessment logics of the French Transparency Committee and link to pricing
  • The German AMNOG procedure in detail
  • NICE appraisals and reforms in the UK
  • Nordic HTA markets and their specific characteristics
  • EU-HTA: status, expectations, and early experiences


Who should attend
This online seminar is designed for professionals and managers working in Market Access, Pricing & Reimbursement, Regulatory Affairs, and related departments within the pharmaceutical industry.

Participants are expected to have a basic understanding of general market access principles.
Aims and objectives
This online seminar provides comprehensive insights to Health Technology Assessment (HTA) logics and practical trends for pharmaceuticals in Europe. Using real-world examples from France, Germany, the United Kingdom and the Nordic countries, the seminar highlights how national assessment processes differ and how they impact market access and pricing.

In addition, it covers the developments around the EU-HTA Regulation, its implementation, and its interactions with national procedures. By the end of the day, you will have a practical overview of current HTA assessment logics, their implications for market access, and emerging European trends.
Your benefit

  • Gain an in-depth understanding of assessment logics and national priorities in key European markets.
  • Learn the methodological approaches of the French Transparency Committee, the German AMNOG process, and NICE appraisals in the UK.
  • Understand how the new EU HTA Regulation will impact existing national processes.
  • Benefit from a direct comparison of different assessment outcomes using a practical pharmaceutical case study.

25112003 Seminar HTA for Pharmaceuticals in Europe: Assessment Logics & Practical Trends

HTA for Pharmaceuticals in Europe: Assessment Logics & Practical Trends

Benefits
  • Insights into national procedures in France, Germany, UK and Nordic countries
  • Practical comparison of national assessment outcomes
  • Officially certified to the ISO 9001 and ISO 21001 standards

Webcode 25112003

Jetzt buchen

JETZT Buchen

Referenten


Alles auf einen Blick

Termin

25/11/2025

25/11/2025

Zeitraum

9:00 - 17:00 Online Training
You may dial in 30 minutes in advance

9:00 - 17:00 Online Training
You may dial in 30 minutes in advance
Veranstaltungsort

online

online

Downloads
Gebühr
Your contact

Dr. Henriette Wolf-Klein
Head of Department

+49 6221 500-680
h.wolf-klein@forum-institut.de

Details

Online seminar on HTA logics, national differences (Germany, France, UK, Nordic countries) and EU HTA regulation - essential insights for pharmaceutical market access professionals.

Topics

  • Principles of HTA in Europe and national implications
  • Assessment logics of the French Transparency Committee and link to pricing
  • The German AMNOG procedure in detail
  • NICE appraisals and reforms in the UK
  • Nordic HTA markets and their specific characteristics
  • EU-HTA: status, expectations, and early experiences


Who should attend
This online seminar is designed for professionals and managers working in Market Access, Pricing & Reimbursement, Regulatory Affairs, and related departments within the pharmaceutical industry.

Participants are expected to have a basic understanding of general market access principles.

Aims and objectives

This online seminar provides comprehensive insights to Health Technology Assessment (HTA) logics and practical trends for pharmaceuticals in Europe. Using real-world examples from France, Germany, the United Kingdom and the Nordic countries, the seminar highlights how national assessment processes differ and how they impact market access and pricing.

In addition, it covers the developments around the EU-HTA Regulation, its implementation, and its interactions with national procedures. By the end of the day, you will have a practical overview of current HTA assessment logics, their implications for market access, and emerging European trends.

Your benefit

  • Gain an in-depth understanding of assessment logics and national priorities in key European markets.
  • Learn the methodological approaches of the French Transparency Committee, the German AMNOG process, and NICE appraisals in the UK.
  • Understand how the new EU HTA Regulation will impact existing national processes.
  • Benefit from a direct comparison of different assessment outcomes using a practical pharmaceutical case study.

Detailed programme

9:00 - 17:00 Online Training
You may dial in 30 minutes in advance

09:00 Welcome and introduction


09:15

Dr. Lisa-Maria Hagemann, Dr. Eva-Maria Reuter

HTA principles in Europe and national implications
  • National priorities and decision making
  • Clinical added benefit
  • Health Economics

10:00 Short break


10:10

Alain Estival

France - Transparency Committee & HAS Methodology
  • Clinical benefit (SMR) and added benefit (ASMR)
  • Evaluation criteria and dossiers
  • Interaction with pricing processes
  • National procedure in conjunction with EU-HTA

11:00 Coffee break


11:15

Dr Thomas Ecker

Germany - The AMNOG Procedure in Depth
  • Early benefit assessment by G-BA & IQWiG
  • Key assessment logic and study requirements
  • Recent updates and negotiation outcomes

12:15 Lunch break


13:15

Claire Blaney

United Kingdom - NICE Appraisals
  • Single Technology Appraisals (STA) and FAD process
  • The role of QALYs and cost-effectiveness
  • Innovative Medicines Fund and reforms

14:00 Short break


14:10

Linnea Oldsberg

Nordic HTA Markets - What to Know
  • Health systems in the Nordic countries
  • Joint assessments and national decisions
  • Practical implications for market access
  • National procedure & conjunction with EU-HTA

15:00 Coffee break


15:15

Dr Stephanie Said

European HTA Regulation - Expectations and first steps
  • Status quo of the JSC and JCAs
  • Implementation timeline and scope
  • National AMNOG procedure & conjunction with EU-HTA

16:15

Dr Thomas Ecker

Case study: One Drug - Three HTAs
  • Practical comparison of assessments in France, Germany, UK
  • Impact of methodology on access and pricing
  • Lessons learned - EU-HTA - the upcoming solution

17:00 Course end


Further information

Technical requirements

You need a reliable Internet connection to take part in our online events. To have the best possible learning experience, we recommend that you use the latest version of the Microsoft Edge or Google Chrome browsers. You will need a headset, loudspeaker or telephone to play the audio. Further information is available here. Please check beforehand that your microphone or headset and camera are working properly. Do not access our services from a VPN since there are issues with the audio over such connections.

We have integrated Zoom video conferencing software into our Learning Space for our online training courses. If you are not authorised to use Zoom, please get in touch with us so we can make alternative arrangements for you to take part in our online training.

This distinguishes our events

of 5 stars of all ratings from 2024

of 5 stars on Trustpilot = good

Recommendations

AMNOG and the EU HTA - Insights into the German Market

This seminar will focus on AMNOG and JCA dossier preparation as well as the German AMNOG procedure in comparison with th...

23.09.2025 in
Details

Pharma Tendermanager

Erhalten Sie praxisnahe Einblicke in das pharmazeutische Tendermanagement - von Vergaberecht über Preisstrategien bis hi...

29. - 30.09.2025 in
Details

Key Account Kassenärztliche Vereinigung

Neue Ideen für eine erfolgreiche Zusammenarbeit mit den KVen: Überblick, Strategie- und Praxistipps

28.08.2025 in
Details

Market Access Krankenhaus

Seminar rund um den Marktzugang Ihrer Produkte im Krankenhaus

24.09.2025 in
Details

Healthcare Management & Market Access-Lehrgang

In 2 Lehrgangstagen erhalten Sie profundes gesundheitspolitisches und gesundheitsökonomisches Know-how sowie Praxiswisse...

27. - 28.08.2025 in
Details

Go forward

List of abbreviations pharma & healthcare

Many abbreviations are used in pharma & healthcare. Download the list of the most important ones.

Details
Abbreviations, Glossary
Newsletter on trends and findings

Stay up to date - we regularly inform you about new regulatory and professional developments.

Details
Professional know-how free of charge
We guarantee the highest quality

We are now officially certified to ISO 9001 and ISO 21001 standard.

Details
We guarantee the highest quality